Latest News and Press Releases

PHOENIX, Nov. 02, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), today reported financial results for its third quarter ended Sept. 30, 2017. OVERALL...

PHOENIX, Oct. 30, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), subsequent to the trading hold placed on its stock on Thursday after market close,...

PHOENIX, Oct. 29, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), today made the following statement about the Department of Justice (DOJ) investigation. ...

PHOENIX, Oct. 29, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), today released the following statement from its president and chief executive officer,...

PHOENIX, Oct. 29, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”) today accepted the resignation of Patrick P. Fourteau from its Board of Directors...

PHOENIX, Oct. 29, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”) today accepted the resignation of the company’s founder, Dr. John N. Kapoor, from its...

PHOENIX, Oct. 19, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), today announced that it will release its third quarter 2017 financial results on...

PHOENIX, Oct. 09, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”) announced today that Saeed Motahari, president and chief executive officer, and Andrew...

PHOENIX, Oct. 09, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that it has extended the compassionate use studies of its proprietary...

PHOENIX, Oct. 06, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the Company”) today released the following statement: We would like to reiterate that we continue to...